Clinical Trial Update: A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update describing a study of Opevesostat (MK-5684) versus a next-generation hormonal agent in metastatic castration-resistant prostate ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Next-generation hormonal agent (NHA)
• Opevesostat (MK-5684)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms | Phase 3 | Status: RECRUITING